Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Merck’

Merck confirms sale of biosimilar division

Merck KGaA has confirmed it intends to sell off its biosimilar drugs division, and is in “advanced discussions” with potential buyers. The German group kicked off its biosimilar programme in 2012 via an agreement with India’s Dr Reddy’s Laboratories, at a time when the company was facing patent expiries on some big-selling products.

Bron: PMLiVE Meer lezen »

MSD’s drug given European approval for first-line treatment in NSCLC

The good news keeps coming for MSD, known as Merck in North America, and Keytruda, with a further label expansion across all 28 EU member states. Keytruda will now be able to be used in first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression.

Bron: InPharm.com Meer lezen »

Merck in $230 million swoop for Vertex cancer programmes

Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 million. Two of the four are clinical trial stage programmes and the remaining two are in preclinical development.

Bron: InPharm.com Meer lezen »

Sanofi and MSD end their joint vaccines partnership

With a new year comes a fresh start, and so it was the case with Sanofi and MSD’s joint vaccine venture, Sanofi Pasteur MSD, which closed its doors and operations on 1 January. The joint operation had been ongoing since 1994 but the two companies decided to integrate the operation into their own facilities in […]

Bron: InPharm.com Meer lezen »

NICE approves MSD’s Keytruda for new cancer indication

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with advanced non-small cell lung cancer who have undergone at least one chemotherapy.

Bron: InPharm.com Meer lezen »

Powerful new data for MSD’s bladder cancer drug stops trial early

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) cancer who have previously been treated with platinum-containing chemotherapy after its performance prompted the early termination of its trial.

Bron: InPharm.com Meer lezen »

Merck invests € 250 million in production value chain in China

Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China’s Essential Drug List.

Bron: World Pharma News Meer lezen »

EMA has validated Merck and Pfizer’s MAA for avelumab

The European Medicines Agency has validated the Marketing Authorisation Application for avelumab for the proposed indication of metastatic Merkel cell carcinoma (MCC).

Bron: InPharm.com Meer lezen »

FDA approves Merck’s lung cancer drug as first-line treatment

Merck & Co said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment.

Bron: Reuters Meer lezen »

MSD’s Keytruda early success ends trial early

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer early having met its primary endpoint, which was to improve overall survival of patients. Keytruda was found to be superior to chemotherapy and the independent Data Monitoring Committee recommended that the trial be stopped early, […]

Bron: InPharm.com Meer lezen »

« Oudere artikelen |